ARID1A is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and leiomyosarcoma as inclusion criteria, 1 is phase 3 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and leiomyosarcoma as inclusion criteria, 1 is phase 3 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and leiomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and leiomyosarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHA is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHA status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHAF2 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHAF2 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHB is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHC is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHC status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHD is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHD status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].